ARCT-021
Vaccine candidate against COVID-19
From Wikipedia, the free encyclopedia
ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | sa-mRNA |
| Clinical data | |
| Other names | LUNAR-COV19 |
| Routes of administration | Intramuscular |
| Identifiers | |
| CAS Number | |
Medical uses
It requires the intramuscular injection with a single dose.[2]
Pharmacology
ARCT-021 is an self-amplifying mRNA vaccine.[3][4]
History
Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine.[5] The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.[6]
Clinical trials
LUNAR-COV19 clinical trials in humans began in July 2020.[7] On 4 January 2021, Arcturus Therapeutics started Phase-2 clinical trials.[8]
Economics
Arcturus has entered into development and supply agreements with the Economic Development Board of Singapore and supply agreements with the Israel Ministry of Health for LUNAR-COV19.[9][10]
.svg){kind=small}
.png){kind=small}
